Synapse - Dean Bajorin

Results (660)

Three-year follow-up from the phase III KEYNOTE-045 trial: Pembrolizumab (Pembro) versus investigator's choice (paclitaxel, docetaxel, or vinflunine) in recurrent, advanced urothelial cancer (UC)

Meeting Abstract

Necchi, A.; Fradet, Y.; Bellmunt, J.; de Wit, R.; Lee, J. L.; Fong, L.; Vozelgang, N. J.; Climent, M. A.; Petrylak, D. P.; Choueiri, T. K.; more...
Annals of Oncology (2019)

Fulltext@MSK | Save

cfDNA is an acceptable but insufficient means of characterizing FGFR3 mutation in patients with metastatic urothelial cancer (mUC)

Meeting Abstract

Pal, S. K.; Bajorin, D. F.; Hoffman-Censits, J. H.; Quinn, D. I.; Petrylak, D. P.; Galsky, M. D.; Vaishampayan, U. N.; De Giorgi, U.; Gupta, S.; Burris, H. A.; more...
Annals of Oncology (2019)

Fulltext@MSK | Save

Health-related quality of life (HRQoL) and updated follow-up from KEYNOTE-057: Phase II study of pembrolizumab (pembro) for patients (pts) with high-risk (HR) non-muscle invasive bladder cancer (NMIBC) unresponsive to bacillus Calmette-Guérin (BCG)

Meeting Abstract

de Wit, R.; Kulkarni, G. S.; Uchio, E.; Boormans, J. L.; Roumiguie, M.; Krieger, L. E. M.; Singer, E. A.; Bajorin, D. F.; Kamat, A. M.; Grivas, P.; more...
Annals of Oncology (2019)

Fulltext@MSK | Save

Propensity-matched analysis of patient-reported outcomes for neoadjuvant chemotherapy prior to radical cystectomy

Journal Article

Feuerstein, M. A.; Goldstein, L.; Reaves, B.; Sun, A.; Goltzman, M.; Morganstern, B. A.; Shabsigh, A.; Bajorin, D. F.; Rosenberg, J. E.; Donat, S. M.; more...
World Journal of Urology (2019)

Fulltext@MSK | Save

5-factor prognostic model for survival of patients with metastatic urothelial carcinoma receiving three different post-platinum PD-L1 inhibitors

Meeting Abstract

Sonpavde, G.; Manitz, J.; Gao, C.; Hennessy, D.; Makari, D.; Niegisch, G.; Rosenberg, J. E.; Bajorin, D. F.; Grivas, P.; Apolo, A. B.; more...
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

KEYNOTE-052: Phase 2 study evaluating first-line pembrolizumab (pembro) in cisplatin-ineligible advanced urothelial cancer (UC): Updated response and survival results

Meeting Abstract

O'Donnell, P. H.; Balar, A. V.; Vuky, J.; Castellano, D. E.; Bellmunt, J.; Powles, T.; Bajorin, D. F.; Grivas, P.; Hahn, N. M.; Plimack, E. R.; more...
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

Pretreatment eosinophil counts (PEC) in metastatic urothelial carcinoma (mUC) treated with anti-PD1/PD-L1 checkpoint inhibitors (CPI)

Meeting Abstract

Mota, J. M.; Teo, M. Y.; Whiting, K.; Ostrovnaya, I.; Li, H.; Lee, C. H.; Funt, S. A.; Callahan, M. K.; Iyer, G.; Bajorin, D. F.; more...
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

A pilot safety study of gemcitabine and cisplatin (GC) with atezolizumab (A) as first-line therapy in patients (pts) with metastatic urothelial cancer (mUC)

Meeting Abstract

Funt, S. A.; Jatwani, K.; Makris, M.; Regazzi, A. M.; Lee, C. H.; Teo, M. Y.; McHugh, D. J.; McCoy, A. S.; Hettich, G.; Wong, P.; more...
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

Biomarkers of outcomes in a randomized phase II trial of first-line paclitaxel, ifosfamide, and cisplatin (TIP) versus bleomycin, etoposide, and cisplatin (BEP) for intermediate- and poor-risk germ cell tumors (GCT)

Meeting Abstract

Feldman, D. R.; Hu, J. S.; Patil, S.; Reuter, V. E.; Srinivas, S.; Stadler, W. M.; Costello, B. A.; Milowsky, M. I.; Appleman, L. J.; Dorff, T. B.; more...
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

Infigratinib in upper tract urothelial carcinoma vs urothelial carcinoma of the bladder and association with comprehensive genomic profiling/cell-free DNA results

Meeting Abstract

Dizman, N.; Rosenberg, J. E.; Hoffman-Censits, J. H.; Quinn, D. I.; Petrylak, D. P.; Galsky, M. D.; Vaishampayan, U. N.; De Giorgi, U.; Gupta, S.; Burris, H. A.; more...
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save